VTGN Earnings Vistagen Therapeutics, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–45 of 45
| Q1 2027 | 2026-06-30 | -0.30 | 2026-08-14 | 10-Q |
| Q4 2026 (derived) | 2026-03-31 | -0.37 | 2026-06-15 | 10-K |
| FY 2026 | 2026-03-31 | -1.83 | 2026-06-15 | 10-K |
| Q3 2026 | 2025-12-31 | -0.45 | 2026-02-12 | 10-Q |
| Q2 2026 | 2025-09-30 | -0.54 | 2025-11-13 | 10-Q |
| Q1 2026 | 2025-06-30 | -0.47 | 2025-08-07 | 10-Q |
| Q4 2025 (derived) | 2025-03-31 | -0.44 | 2025-06-17 | 10-K |
| FY 2025 | 2025-03-31 | -1.67 | 2025-06-17 | 10-K |
| Q3 2025 | 2024-12-31 | -0.46 | 2025-02-13 | 10-Q |
| Q2 2025 | 2024-09-30 | -0.42 | 2024-11-07 | 10-Q |
| Q1 2025 | 2024-06-30 | -0.35 | 2024-08-13 | 10-Q |
| Q4 2024 (derived) | 2024-03-31 | 0.30 | 2024-06-11 | 10-K |
| FY 2024 | 2024-03-31 | -1.52 | 2024-06-11 | 10-K |
| Q3 2024 | 2023-12-31 | -0.22 | — | — |
| Q2 2024 | 2023-09-30 | -0.66 | — | — |
| Q1 2024 | 2023-06-30 | -0.94 | — | — |
| FY 2023 | 2023-03-31 | -8.51 | — | — |
| FY 2016 | 2016-03-31 | -872.40 | 2016-06-24 | 10-K |
| Q3 2016 | 2015-12-31 | -58.50 | 2016-02-16 | 10-Q |
| Q2 2016 | 2015-09-30 | -157.80 | 2015-11-16 | 10-Q |
| Q4 2015 | 2015-03-31 | -127.20 | 2015-06-29 | 10-K |
| FY 2015 | 2015-03-31 | -318.30 | 2015-06-29 | 10-K |
| Q3 2015 | 2014-12-31 | -32.40 | 2015-02-17 | 10-Q |
| Q2 2014 | 2014-09-30 | -57.00 | 2014-11-19 | 10-Q |
| Q1 2014 | 2014-06-30 | -111.00 | 2014-08-12 | 10-Q |
| Q4 2014 | 2014-03-31 | -47.10 | — | — |
| FY 2014 | 2014-03-31 | -114.30 | 2014-06-25 | 10-K |
| Q3 2013 | 2013-12-31 | -13.20 | 2014-02-14 | 10-Q |
| Q2 2014 | 2013-09-30 | -41.10 | — | — |
| Q1 2013 | 2013-06-30 | -13.20 | 2013-08-14 | 10-Q |
| Q4 2012 | 2013-03-31 | -5.70 | 2013-07-18 | 10-K |
| FY 2012 | 2013-03-31 | -0.60 | 2013-07-18 | 10-K |
| Q3 2012 | 2012-12-31 | -25.50 | — | — |
| Q2 2012 | 2012-09-30 | -3.30 | 2012-11-14 | 10-Q |
| Q1 2012 | 2012-06-30 | -3.30 | 2012-08-14 | 10-Q |
| Q4 2011 | 2012-03-31 | -5.40 | — | — |
| FY 2011 | 2012-03-31 | -24.90 | 2012-07-02 | 10-K |
| Q3 2011 | 2011-12-31 | -8.40 | 2012-02-14 | 10-Q |
| Q2 2011 | 2011-09-30 | -4.50 | 2011-11-14 | 10-Q |
| Q1 2011 | 2011-06-30 | -6.60 | 2011-08-22 | 10-Q |
| Q4 2010 (derived) | 2011-03-31 | -20.10 | — | — |
| FY 2010 | 2011-03-31 | -54.30 | — | — |
| Q3 2010 | 2010-12-31 | -19.50 | — | — |
| Q2 2010 | 2010-09-30 | -9.00 | — | — |
| Q1 2010 | 2010-06-30 | -5.70 | — | — |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.